Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes

Blake A Niccum; Jonathan G Stine; Javelle A Wynter; Virginia Kelly; Stephen H Caldwell; Neeral L Shah

doi:10.2337/cd18-0112

Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes

Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.

Authors

Blake A Niccum¹, Jonathan G Stine², Javelle A Wynter³, Virginia Kelly³, Stephen H Caldwell³, Neeral L Shah³

Affiliations

¹ Department of Internal Medicine, Massachusetts General Hospital, Boston, MA.
² Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
³ Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA.

Abstract

Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.